Induction Of Pluripotent Stem Cells From Adult Human Fibroblasts By Defined Factors

Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Cell (Impact Factor: 32.24). 12/2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019
Source: PubMed


Successful reprogramming of differentiated human somatic cells into a pluripotent state would allow creation of patient- and disease-specific stem cells. We previously reported generation of induced pluripotent stem (iPS) cells, capable of germline transmission, from mouse somatic cells by transduction of four defined transcription factors. Here, we demonstrate the generation of iPS cells from adult human dermal fibroblasts with the same four factors: Oct3/4, Sox2, Klf4, and c-Myc. Human iPS cells were similar to human embryonic stem (ES) cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity. Furthermore, these cells could differentiate into cell types of the three germ layers in vitro and in teratomas. These findings demonstrate that iPS cells can be generated from adult human fibroblasts.

112 Reads
    • "Recent advancement in stem cell research makes it possible to generate and propagate induced pluripotent stem cells (iPSCs) from skin biopsy or urine samples (containing exfoliated renal epithelial cells; Takahashi et al., 2007; Yu et al., 2007; Zhou et al., 2012). DNA can then be extracted from iPSC cultures for use in genetic analyses. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Quality sleep is critical for daily functions of human beings and thus the timing and duration of sleep are tightly controlled. However, rare genetic variants affecting sleep regulatory mechanisms can result in sleep phenotypes of extremely deviated sleep/wake onset time or duration. Using genetic analyses in families with multiple members expressing particular sleep phenotypes, these sleep-associated genetic variants can be identified. Deciphering the nature of these genetic variants using animal models or biochemical methods helps further our understanding of sleep processes. In this chapter, we describe the methods for studying genetics of human sleep behavioral phenotypes. © 2015 Elsevier Inc. All rights reserved.
    Methods in enzymology 12/2015; 552:309-24. DOI:10.1016/bs.mie.2014.10.046 · 2.09 Impact Factor
  • Source
    • "5. First-in-human clinical trial of iPSC-based therapy Nobel prize-winning stem cell researcher Shinya Yamanaka gave a keynote lecture at the symposium and celebrated the firstin-human clinical trial using iPSCs led by Masayo Takahashi, a RIKEN researcher [6e8]. iPSCs are a type of pluripotent stem cell able to differentiate into multiple cell types such as neuron, hepatocyte , cardiomyocyte and beta cells [9]. Yamanaka described the aim of the Center for iPS Cell Research and Application (CiRA), where he is based, to start clinical trials using iPSCs, and examined the challenges involved in this work. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Symposium of Regenerative Medicine for Patients, organized by the Japanese Society for Regenerative Medicine, was held on 28 September 2014 in Tokyo, Japan. The event provided an overview of the important areas of cell-based medicine, and highlighted the first-in-human clinical trial of induced pluripotent stem cell (iPSC)-derived products. Recent advances in regenerative medicine were also discussed, especially regarding the use of somatic cells such as chondrocytes, skeletal myocytes and cardiomyocytes under both the Act on the Safety of Regenerative Medicine, and the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act.
  • Source
    • "Screening of 24 factors by the Yamanaka´s group which are sufficient to revert the somatic cells to a pluripotent state demonstrated that generation of iPSCs required a combination of only four transcription factors (Oct4, Sox2, Klf4, c-myc) (Takahashi and Yamanaka 2006). In 2007, the same group succeeded in generating human iPSCs using genes encoding the same four transcription factors (Takahashi et al. 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular and neurodegenerative diseases are the most common health threats in developed countries. Limited cell derivation and cell number in cardiac tissue makes it difficult to study the cardiovascular disease using the existing cardiac cell model. Regarding the neurodegenerative disorders, the most potential sources of cell therapeutics such as fetal-derived primary neurons and human embryonic stem cells (ESCs) are associated with ethical or technical limitations. The successful derivation of human-induced pluripotent stem cells (iPSCs) by de-differentiation of somatic cells offers significant potential to overcome hurdles in the field of the replacement therapy. Human iPSCs are functionally similar to human embryonic stem cells, and can be derived autologously without the ethical challenges associated with human ESCs. The iPSCs can, in turn, be differentiated into all cell types including neurons, cardiac cells, blood and liver cells, etc. Recently, target tissues derived from human iPSCs such as cardiomyocytes (CMs) or neurons have been used for new disease modeling and regenerative medicine therapies. Diseases models could be advantageous in the development of personalized medicine of various pathological conditions. This paper reviews efforts aimed at both the practical development of iPSCs, differentiation to neural/cardiac lineages, and the further use of these iPSCs-derived cells for disease modeling, as well as drug toxicity testing.
    General Physiology and Biophysics 10/2015; DOI:10.4149/gpb_2015023 · 1.17 Impact Factor
Show more